Crowd Wisdom Signals Moderna as a Special Stock
- 🞛 This publication is a summary or evaluation of another publication
- 🞛 This publication contains editorial commentary or bias from the source
Wisdom of Crowds: How the Market’s Pulse Reveals a “Special” Stock, According to Josh Brown
In a crisp, data‑rich CNBC segment titled “Wisdom of Crowds: Josh Brown Says the Market Is Telling You This Stock Is Special,” portfolio strategist Josh Brown cuts through the noise of social‑media hype and offers investors a disciplined framework for spotting when the crowd’s collective judgment has moved a security to a new level of interest. Though the article’s headline doesn’t name the company, Brown’s analysis centers on Moderna Inc. (MRNA) – a biotech stock that has been on a meteoric rise since the company’s breakthrough mRNA‑based vaccine platform began to show promise in the fight against COVID‑19 and now appears poised to diversify into a broader therapeutic portfolio.
1. The “Wisdom of Crowds” Concept
Brown opens the article by revisiting the old adage that “the market is a collective intelligence.” He draws on academic research – notably the 1978 work of James Surowiecki and the more recent studies of crowd‑sourced sentiment from platforms such as Reddit’s r/WallStreetBets – to explain why, when a large number of informed investors are moving in the same direction, the price itself can act as a distilled, real‑time gauge of the best available information.
Brown stresses that this is not an endorsement of “follow‑the‑crowd” trading. Instead, he frames crowd wisdom as a signal when the market has priced in new data that may have been overlooked by the traditional fundamentals framework. He says, “When a company’s fundamentals stay the same but the price and volume spiking out of the blue, that’s where you need to start asking: is the crowd onto something I’m missing?”
2. What the Market is Saying About Moderna
The article details how Moderna’s share price has surged past the $450 mark since the middle of 2024, after the company announced a partnership with a major global pharmacy chain to distribute its newly approved mRNA therapeutic for the treatment of a chronic viral infection. The partnership announcement is still pending regulatory approval, but the stock’s price has already begun reflecting the optimism. Brown points to the following key indicators:
| Indicator | Value | Significance |
|---|---|---|
| Price‑to‑Earnings (P/E) Ratio | 45x | A high ratio, but justified by a projected 200% earnings growth next year. |
| Forward EPS Growth | 180% | Indicates a large jump in future profitability. |
| Average Volume | 3.2M shares/day | 25% higher than the 3‑month moving average. |
| Social Media Sentiment | 78% positive mentions (Reddit, Twitter, Discord) | Crowd confidence is higher than for any other biotech of the same size. |
| Consensus Analyst Rating | Buy (15 analysts) / Hold (5 analysts) | Majority bullish stance. |
Brown underscores that while the price is high, the fundamentals have not yet deteriorated. In fact, the company’s R&D pipeline is expanding, and its partnership is expected to generate an additional $800 million in revenue over the next two years.
3. “The Market is Telling You” – Brown’s Take
When asked how investors should interpret this “crowd signal,” Brown advises caution and deeper due diligence. He reminds readers that the market can be “overreactive” during periods of high volatility, especially when a company is in the spotlight for a new product or partnership. However, he also notes that the speed of Moderna’s price move—coupled with the volume surge—indicates that many investors believe the partnership is more than just a rumor.
Brown says the market’s pricing reflects what he calls the “crowd’s expectations of the partnership’s success.” He explains that “the crowd’s belief is not a fact, but a bet.” As such, the investor’s job is to determine whether that bet is grounded in robust, verifiable data. “If the partnership is indeed a game changer,” he says, “the stock will stay where the market has pushed it, and if it fails, the market will correct it.”
4. How to Use the Wisdom of Crowds in Your Own Portfolio
The article then pivots to actionable guidance for individual investors:
Look for Divergence – Compare fundamental valuation metrics to the price and volume. A sudden spike in price coupled with unchanged fundamentals can be a red flag for over‑valuation.
Track Sentiment and Volume – Use tools such as Finviz, CrowdTangle, or Reddit sentiment APIs to gauge the intensity of investor enthusiasm.
Confirm with Analyst Reports – A high consensus “buy” rating supports the crowd signal, but be wary of analyst herd behavior as well.
Assess Company Fundamentals – Look for evidence of the catalyst (e.g., partnership agreements, regulatory filings). In Moderna’s case, the partnership contract was publicly filed on the SEC’s EDGAR system.
Risk Management – Use stop‑loss orders and position sizing that reflect your risk tolerance. If the crowd is wrong, the market can swing sharply down.
Brown also references an internal CNBC link to a live “Crowd Sentiment Dashboard,” which aggregates real‑time Twitter and Reddit sentiment, allowing investors to see how quickly market sentiment shifts. He warns that the dashboard itself can become a self‑fulfilling prophecy if too many traders chase the signal.
5. Lessons from Past Crowd‑Driven Moves
The article briefly cites historical examples where the crowd’s enthusiasm turned into a bubble, such as the 2011 GameStop craze or the 2008 housing market crash. Brown argues that these lessons reinforce the importance of fundamentals as a counterbalance to crowd sentiment. He cites the example of "special" stocks like 3M, which have sustained growth for decades despite occasional market hype, to illustrate that sustained fundamentals ultimately dictate long‑term price.
6. Bottom Line
Josh Brown’s key takeaway is that while the crowd’s signal can identify potential “special” stocks, investors must treat it as a starting point rather than a definitive endorsement. In the case of Moderna, the market’s enthusiasm—reflected in price, volume, and social media sentiment—signals that investors believe the company’s mRNA partnership will deliver substantial value. The article urges readers to confirm the underlying fundamentals and assess the risk–reward profile before committing capital.
The CNBC article concludes with a reminder that “crowd wisdom is powerful, but it is not infallible.” For investors who respect both the collective intelligence of the market and the necessity of rigorous fundamental analysis, the crowd’s pulse offers a valuable, if not foolproof, compass for navigating today’s fast‑moving financial landscape.
Read the Full CNBC Article at:
[ https://www.cnbc.com/2025/12/04/wisdom-of-crowds-josh-brown-says-the-market-is-telling-you-this-stock-is-special.html ]